Primaxin (cilastatin/imipenem) / Abbott - LARVOL DELTA

A case of portal venous gas caused by the use of a nasojejunal nutrition tube. (PubMed, J Int Med Res) - "This patient was discharged after 1 week of treatment with imipenem/cilastatin sodium for anti-infection, gastrointestinal decompression, fluid replacement, and pain relief, and the patient's abdominal pain was significantly relieved...The successful treatment of this patient highlights that addressing physical factors, providing gastrointestinal decompression, and administering anti-infection therapy can aid in the management of such cases. Bacterial culture of gastric juice and drug sensitivity testing can guide effective anti-infection treatment."

Journal • Infectious Disease • Nephrology • Pain • Pulmonary Disease • Respiratory Diseases

Clinical study of polymyxin E sodium mesylate in the treatment of carbapenem-resistant gram-negative bacteria (CRO) infection in critically ill patients (ChiCTR) - P4 | N=40 | Recruiting | Sponsor: Hangzhou Linping Hospital of Traditional Chinese Medicine; Hangzhou Linping Hospital of Traditional Chinese Medicine

New P4 trial • Infectious Disease

Clinical Outcomes of Shoulder Artery Embolization for Adhesive Capsulitis. (PubMed, Cardiovasc Intervent Radiol) - "TAE achieved pain reduction and functional improvement in patients with adhesive capsulitis refractory to conservative treatments."

Clinical data • Journal • Pain

Disseminated Nontuberculous Mycobacterial Infection Following Cerebral Shunt Infection Caused by Mycobacterium fortuitum: A Case Report and Literature Review. (PubMed, Intern Med) - "We diagnosed the patient with disseminated nontuberculous mycobacterial infection due to M. fortuitum and removed the ventriculoatrial shunt. Multiple antimicrobial agents (imipenem/cilastatin, linezolid, ciprofloxacin, and trimethoprim/sulfamethoxazole) were administered for approximately two months, and the symptoms improved."

Journal • CNS Disorders • Infectious Disease • Nontuberculous Mycobacterial Disease • Respiratory Diseases • Ventriculomegaly

TARGETING PAIN IN THE FIRST METATARSOPHALANGEAL JOINT: A NEW COMPLEMENTARY APPROACH IN RHEUMATOLOGY AND INTERVENTIONAL RADIOLOGY COLLABORATION USING EMBOLIZATION (EULAR 2025) - "Imipenem/cilastatin-based embolization offers a minimally invasive, effective alternative for managing refractory MTPJ pain of various etiologies. The technique demonstrates significant improvements in pain relief and functional outcomes, with a favorable safety profile compared to surgical interventions. Future studies involving larger cohorts, multi-center settings, and long-term follow-up are needed to validate its safety, efficacy, and sustained clinical benefits."

Anesthesia • Ankylosing Spondylitis • Gout • Immunology • Inflammation • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis

A new treatment alternative for patients with painful hand osteoarthritis: Early results of the efficacy and safety of intraarterial imipenem-silastatin therapy (EULAR 2025) - "All patients (100%) had previously used NSAIDs, seven patients (77.8%) had low-dose glucocorticoids, five patients (55.6%) had colchicine, four patients (44.4%) had hydroxychloroquine and two patients (22.2%) had a history of biologic disease-modifying anti-rheumatic drug (DMARD) use due to misdiagnosis. In clinical practice, treatment options for patients with painful hand OA are very limited. A study by Kubo T et al. from Japan demonstrated the efficacy and safety of intra-arterial imipenem-cilastatin+iodinated contrast embolisation in 92 patients with hand OA in 2023 [1]."

Clinical • Dermatology • Immunology • Musculoskeletal Diseases • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology • Urticaria

A rare case of multiple brain abscesses caused by Nocardia abscessus co-infection with tuberculous meningitis in an immunocompetent patient. (PubMed, BMC Infect Dis) - "Nocardial brain abscesses are associated with a high mortality rate, especially among immunocompromised patients and those with multiple abscesses. Prompt diagnosis, aggressive surgical intervention, and sensitive antibiotic treatment offer the best prospects for curing nocardiosis. Tuberculous meningitis, the most lethal manifestation of Mycobacterium tuberculosis infection, often leads to severe outcomes primarily due to delayed diagnosis and treatment. The GeneXpert/RIF assay, an emerging diagnostic tool, provides a more sensitive and rapid means of detecting TBM. For patients with a high clinical suspicion of TBM, empirical anti-tuberculosis treatment should be initiated immediately. Timely and accurate management, coupled with continuous monitoring of the patient's condition, is crucial for achieving a favorable prognosis."

Journal • CNS Disorders • Infectious Disease • Pain • Pneumonia • Pulmonary Disease • Respiratory Diseases • Septic Shock • Tuberculosis • Ventriculomegaly

Application of metagenomic next-generation sequencing in the diagnosis and treatment of acute pneumonia caused by Tropheryma whipplei. (PubMed, BMC Pulm Med) - "The mNGS examination of bronchoalveolar lavage fluid can significantly improve the early diagnosis of acute pneumonia caused by Tropheryma whipplei. The treatment involving imipenem-cilastatin combined with SMZ-TMP, followed by oral SMZ-TMP for three months, is effective."

Biomarker • Journal • Next-generation sequencing • Infectious Disease • Pneumonia • Respiratory Diseases

Antibacterial efficacy of cefoperazone/sulbactam in combination with various antimicrobials against carbapenem-resistant Klebsiella pneumoniae. (PubMed, Acta Microbiol Immunol Hung) - "However, the current therapy for CRKP infection is polymyxin and tigecycline. The aim of this study is to analyze the in vitro antibacterial effects of cefoperazone/sulbactam (SCF) combined with ceftazidime (CAZ), imipenem/cilastatin (IMI), and meropenem (MEM) against CRKP harbouring different antibiotic resistance genes...The results of time-kill curve showed that SCF combined with IMI had good antibacterial effect. This study found that SCF combined with IMI has a synergistic antibacterial effect on KPC producing carbapenem-resistant K. pneumoniae, which could provide reference for clinical practice."

Journal • CNS Disorders • Infectious Disease • Pneumonia • Respiratory Diseases • Septic Shock

Continuous versus intermittent bolus dosing of beta-lactam antibiotics in a South African multi-disciplinary intensive care unit: a randomized controlled trial. (PubMed, J Infect) - "Among critically ill patients meeting the sepsis-3 definition, this study could not demonstrate superiority of continuous infusion of beta-lactam antibiotics compared to intermittent bolus in achieving clinical cure."

Journal • Critical care • Human Immunodeficiency Virus • Infectious Disease • Septic Shock

Case Report: Nanopore Sequencing-Based Detection of Pulmonary Nocardiosis Caused by Nocardia Otitidiscaviarum in an Immunocompetent Patient. (PubMed, Infect Drug Resist) - "The patient's symptoms and signs showed improvement following treatment with imipenem cilastatin, linezolid and SMZ/TMP. This case presents a pulmonary infection caused by N. otitidiscaviarum in an immunocompetent patient, where the pathogen was identified within 4 hours through NS. This rapid and accurate diagnostic approach offers significant advantages for the timely diagnosis of pulmonary nocardiosis."

Journal • Infectious Disease • Respiratory Diseases

CUPPING THERAPY GONE AWRY: A CASE OF ACINETOBACTER ENDOCARDITIS AND PULMONARY SEPTIC EMBOLI IN A HEALTHY YOUNG ADULT - Mohanad Qwaider (ACC 2025) - "Empirical treatment with vancomycin and gentamicin was initiated. Blood cultures revealed the growth of Acinetobacter species.Decision-making: Based on blood culture susceptibility results, the regimen was modified to imipenem-cilastatin and trimethoprim-sulfamethoxazole for a total of 6 weeks, resulting in a significant clinical response... Although it is rare, Acinetobacter can cause IE of a native valve even in healthy individuals. Detailed patient history and appropriate diagnostic testing are crucial."

Clinical • Cardiovascular • Heart Failure • Infectious Disease • Pneumonia • Pulmonary Embolism • Respiratory Diseases

Aeromonas veronii-induced septic arthritis of the hip in a child with acute lymphoblastic leukemia. (PubMed, Open Life Sci) - "The child's condition was successfully treated with a combination of amikacin and imipenem-cilastatin, leading to improvement and subsequent discharge in a satisfactory state. SAH caused by A. veronii is a rare occurrence, and the utilization of mNGS holds significant potential for the early detection of uncommon infections in immunosuppressed children."

Journal • Acute Lymphocytic Leukemia • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Oncology • Pain • Rheumatology

HRS-8427 versus imipenem-cilastatin for complicated urinary tract infections: a randomised, double-blind phase 2 study (ESCMID Global 2025) - No abstract available

Clinical • Late-breaking abstract • P2 data • Infectious Disease • Nephrology

Are meropenem or imipenem-cilastatin effective therapies for patients with invasive ertapenem-resistant infections? (ESCMID Global 2025) - No abstract available

Clinical • Infectious Disease

Transcatheter Arterial Embolization as a Treatment for Chronic Pain due to Osteoarthritis. (PubMed, Cardiovasc Intervent Radiol) - "TAE appears to be a feasible and safe minimally-invasive option for selected TMJ-OA patients with symptoms refractory to standard treatments. Further studies with larger cohorts and extended follow-up are warranted to confirm these preliminary findings."

Journal • Immunology • Musculoskeletal Diseases • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

Ultrasound-guided thoracentesis for diagnosing Nocardia beijingensis-related empyema in a patient with systemic lupus erythematosus: A rare case report. (PubMed, Radiol Case Rep) - "We present a case of a 49-year-old female patient with SLE on immunosuppressive therapy (corticosteroids and azathioprine), admitted with dyspnea and left-sided pleuritic chest pain...The patient received empirical intravenous antibiotic therapy with imipenem/cilastatin and vancomycin without isolating the causative organism for 10 days...Ultrasound-guided aspiration, targeting the loculated and encapsulated effusion, played a crucial role in confirming the diagnosis. Empirical treatment with imipenem/cilastatin combined with long-term oral trimethoprim/sulfamethoxazole was found to be effective."

Journal • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Pain • Pulmonary Disease • Respiratory Diseases • Systemic Lupus Erythematosus

Fighting resistance with redundancy: a path forward for treating antimicrobial-resistant infections? (PubMed, Antimicrob Agents Chemother) - "Sulbactam-durlobactam was combined with imipenem-cilastatin in a clinical trial that led to its United States Food and Drug Administration approval. However, the additive benefit of imipenem remains uncertain. In a recent study (Antimicrob Agents Chemother 69:e01627-24, 2025, https://doi.org/10.1128/aac.01627-24), Veeraraghavan and colleagues provide convincing mechanistic evidence that adding imipenem to sulbactam-durlobactam enhances bacterial killing, likely through complementary inhibition of penicillin binding proteins, leveraging the concept of target redundancy."

Journal • Infectious Disease

Comparative Safety of Three Temporary Embolic Agents in Transcatheter Arterial Embolization for Degenerative, Inflammatory, and Overuse Joint Disorders. (PubMed, J Vasc Interv Radiol) - "IPM/CS, QS-GSPs, and RMs demonstrated acceptable safety profiles and effectively alleviated symptoms in TAE for degenerative, inflammatory, and overuse joint disorders."

Journal • Immunology • Musculoskeletal Pain • Orthopedics • Osteoarthritis • Pain • Rheumatology

Physical compatibility of ceftazidime-avibactam with selected intravenous antimicrobials in simulated Y-site administration. (PubMed, Eur J Hosp Pharm) - "Ceftazidime-avibactam was physically compatible with the selected intravenous antimicrobials (tigecycline, metronidazole, meropenem, imipenem and cilastatin, fosfomycin, aztreonam and vancomycin) in simulated Y-site administration."

Journal

Real-world pharmacovigilance investigation of imipenem/cilastatin: signal detection using the FDA Adverse Event Reporting System (FAERS) database. (PubMed, Front Pharmacol) - "Clinicians should pay further attention to the implications of numerous AEs and their corresponding signal intensities, as well as unrecorded signals of severe AEs. This holds significant value in enhancing the clinical safety profile of IMI/CIL."

Adverse events • Journal • Real-world evidence • CNS Disorders • Infectious Disease

Mycobacterium goodii pulmonary disease in an immunocompetent patient: A case report and literature review. (PubMed, J Infect Chemother) - "The patient was responded well to the initial therapy with amikacin, imipenem/cilastatin, doxycycline, sulfamethoxazole/ trimethoprim, and clarithromycin, followed by 18 months of ambulatory treatment with doxycycline, sulfamethoxazole/ trimethoprim, clarithromycin, and sitafloxacin. In this case, the development of M. goodii pulmonary disease is might be associated with the history of gastrectomy. For identifying the pathogen, MALDI-TOF MS and whole genome sequencing analysis were useful and the intensive initial treatment in accordance with the drug susceptibility testing was successful."

Journal • Cough • Infectious Disease • Peptic Ulcer • Pulmonary Disease • Respiratory Diseases • Tuberculosis

β-Lactam/β-Lactamase Inhibitor Combination Antibiotics Under Development. (PubMed, Pathogens) - "The incorporation of ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam, and imipenem/cilastatin/relebactam has provided new therapeutic options in the treatment of patients with infections due to MDR pathogens. Cefiderocol along with cefepime/enmetazobactam, avibactam/aztreonam, and sulbactam/durlobactam have been recently added to these agents as therapeutic choices, particularly for metallo-β-lactamase producing Gram-negative bacteria...However, only a few have advanced through phase 1, 2, and 3 clinical trials. Among them, in this article, we focus on the most promising combinations of cefepime/zidebactam, cefepime/taniborbactam, and imipenem/cilastatin/funobactam, which are currently under investigation in phase 3 trials."

Journal • Review • Infectious Disease

Innovative Antibiotic Therapies for Carbapenem-Resistant Gram-Negative Bacterial Infections: Clinical Efficacy, Safety, and Comparative Studies. (PubMed, Microorganisms) - "Cefiderocol has shown superior outcomes in complicated urinary tract infections (cUTI) compared to imipenem-cilastatin. A comparison of colistin monotherapy versus combination therapy with meropenem for carbapenem-resistant infections revealed no significant improvement in clinical outcomes with combination therapy but noted delays in resistance development. Colistin-rifampicin combination therapy showed potential benefits for colistin-resistant Acinetobacter baumannii, although results were not statistically significant. SPR206, a polymyxin derivative, and durlobactam, a β-lactamase inhibitor, show promise in addressing these resistant strains, with durlobactam demonstrating efficacy in combination with sulbactam and imipenem-cilastatin. Additional studies investigated antibiotic strategies for resistant infections, including cefoperazone-sulbactam versus combination therapy with tigecycline, and examined infection-prevention strategies in surgical settings, comparing..."

Journal • Review • Infectious Disease • Nephrology • Pneumonia • Respiratory Diseases

Clinical and Radiological Outcomes of Transarterial Embolization for Adhesive Capsulitis. (PubMed, Korean J Radiol) - "TAE may be an effective and safe therapeutic approach for AC refractory to conservative treatments, alleviating pain and supporting functional recovery. The observed MRI findings suggest that the effectiveness of TAE for AC may be attributed to the reduction of inflammation and the elimination of angiogenesis."

Journal • Retrospective data • Inflammation • Pain